Kornimate/medical-research-clean huggingface dataset:
effect of dexamethasone combined with ondansetron on postoperative nausea and vomiting in patients with patient-controlled analgesia after video-assisted thoracoscopic surgery

Conditions: Nausea; Vomiting

Summary: the purpose of this study is to study the effect of dexamethasone combined with ondansetron on postoperative nausea and vomiting in patients with patient-controlled analgesia after video-assisted thoracoscopic surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing video-assisted thoracoscopic surgery * age 20-75 * american society of anesthesiologists physical status classification i or ii exclusion criteria: * antiemetic within 24 hrs * taking steroids, opioids within 1 week * active drug or alcohol abuse * gi motility disorder, severe renal/ hepatic disease.

Keywords: postoperative nausea and vomiting after video-assisted thoracoscopic surgery
retrospective analysis of rituximab-containing immunochemotherapy for burkitt's or burkitt-like lymphoma in adults

Conditions: Burkitt's Lymphoma; High-grade B-cell Lymphoma

Summary: this retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with burkitt's lymphoma (bl) or high-grade b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and bl.

inclusion criteria 1. pathologically confirmed bl or bl-u by world health organization 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion 5. with complete set of clinical and laboratory data for the analysis

Eligibility criteria:
inclusion criteria: 1. pathologically confirmed burkitt's lymphoma (bl) or high grade b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and bl (bl-u) by who 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion exclusion criteria: 1. patients with bl or bl-u previously treated with rituximab
nmes in critically ill patients

Conditions: Critically Ill Patients With a Predicted Prolonged ICU Stay

Summary: critically ill patients with a predicted prolonged icu stay will receive neuromuscular electrical stimulation (nmes) of one quadriceps muscle. whether the dominant or non-dominant side will be stimulated is chosen randomly by using opaque sealed envelopes. the patients will receive electrical stimulation for 1h for 7 consecutive days. the stimulated and non-stimulated side will be compared for it's thickness (by using ultrasound imaging), muscle strength if the patients are awake and cooperative (using the medical research council scale and handheld dynamometry) and a muscle biopsy will be taken. as a primary outcome the investigators hypothesize that electrical stimulation will preserve muscle mass with respect to the non-stimulated quadriceps. as secondary outcomes the investigators hypothesize that electrical stimulation can reduce muscle strength loss and leads to a better protein balance and thicker muscle fibers in the stimulated quadriceps.


Eligibility criteria:
inclusion criteria: * all adult icu patients with a predicted prolonged icu stay exclusion criteria: * preexisting neuromuscular disease, polyneuropathy or myopathy (e.g. guillain-barré, myasthenia gravis, amyotrophic lateral sclerosis, paraplegia, multiple sclerosis, ...) * receiving neuromuscular blocking agents * musculoskeletal conditions of the pelvis and/or lower limb (e.g. fractures, skin disease ) * focal neurological conditions of the pelvis and/or lower limb * skin disease (e.g. burns) * presence of a pace-maker or defibrillator * hemodynamic or respiratory instability, active cardiac ischemia * high fever (\>39°) * pregnancy * brain death * intracranial pressure \>20 mmhg * an anticipated fatal outcome * psychiatric disorders or severe agitation * re-admission to the icu
osteoporosis and fall prevention education

Conditions: Osteoporosis

Summary: objective: the study is to increasing osteoporosis awareness with fracture risk assessments and management as well as fall prevention among elderly in northern region of taiwan. method: six community osteoporosis and fall prevention educational programme will be held at northern region of taiwan. a questionnaires design including demographic variables , frax variables, nutritional variables and osteoporosis and fall knowledge variables as well.the pretest-posttest method was used to analyse the effect on education. expected outcomes : (1)fall prevention educational programme will hold in northern region of taiwan at different communities in order to increasing osteoporosis awareness with fracture risk assessment tool, establishing fall knowledges among elderly and some fall prevention skills.(2)elderly with 10-year probability of major osteoporotic fracture risk who more than 20% and 10-year probability of hip fracture risk who more than 3% will identify as high risk of osteoporosis. (3) to estimate number of cases who identified as high risk will recommend for bmd measurement.


Eligibility criteria:
inclusion criteria: 1. adults between the ages of 40 to 90. 2. adults who been fractures prior to assessment. 3. adults who have ability, well conscious to complete the questionnaires. exclusion criteria: 1.adults who have treatment currently will not include in this study.

Keywords: osteoporosis fall prevention high risk population
a research study comparing active drug in the blood in healthy participants following dosing of the current and a new formulation (d) semaglutide tablets

Conditions: Healthy Volunteers; Type 2 Diabetes

Summary: in this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. one is the current formulation and the other one is a new formulation of semaglutide. both will be administered as a tablet and are for the treatment of diabetes. currently, semaglutide is only prescribed as injections for the treatment of diabetes in some countries. the aim of this study is to find out if the dosage strength of the current formulation of semaglutide can be reduced in the new tablet formulation. for this purpose, it will be measured how much semaglutide is taken up in the body from the two (2) different tablet formulations each with three (3) different dosage strengths. the tablet version of the study medicine is a new medicine that cannot yet be prescribed. participants will either get semaglutide in the current tablet formulation previously tested in many large studies, or get the tablet that contains semaglutide in a new formulation - which treatment is decided by chance. participants will get one tablet per day over 4 weeks in each of the 3 treatment periods (i.e. treatment in a total of 12 weeks). the tablets should be taken in the morning together with half a glass of water (120 ml), after an overnight fast of at least 6 hours (no food or drinks). furthermore, water is not allowed from 2 hours before dosing. after dosing participants must wait 30 minutes before they may eat or drink. at home, participants must take their breakfast 30-45 minutes after dosing.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-64 years (both inclusive) at the time of signing informed consent. * body mass index between 20.0 kg/m\^2 and 29.9 kg/m\^2 (both inclusive). * considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * glycated haemoglobin (hba1c) equal to or above 6.5 % (48 mmol/mol) at screening. * use of tobacco and nicotine products, defined as any of the below: * smoking more than 5 cigarettes or the equivalent per day * not willing to refrain from smoking and use of nicotine substitute products during the in-house period(s) * history (as declared by the subject) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery). * presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator. * personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject). * history (as declared by the subject) or presence of pancreatitis (acute or chronic).
guangzhou women's health cohort study (gwhcs)

Conditions: Cervical Cancer; Breast Cancer; Lung Cancer; Colorectal Cancer; Endometrial Cancer; Ovarian Cancer; Hypertension; Diabetes; Reproductive Disorder

Summary: the guangzhou women's health cohort study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in guangzhou. based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . the cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of guangzhou with a scale of 1 million by 2030.

the guangzhou women's health cohort study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in guangzhou. based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . the cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of guangzhou with a scale of 1 million by 2030.

Eligibility criteria:
inclusion criteria: * women aged 35-64 years old * women with registered permanent residence in guangzhou * women with informed consent exclusion criteria: * women without informed consent * women with reading and/or writing difficulties * women with serious mental disorders
integrated cbt to improve functioning in veterans with anxiety and substance use

Conditions: Anxiety Disorder; Posttraumatic Stress Disorder; Hazardous Drinking

Summary: individual with anxiety and post-traumatic stress disorder often use alcohol in ways that could cause them harm. treating both mental health concerns and alcohol use at the same time can help reduce difficulties engaging in multiple treatments. the investigators are evaluating how a cognitive behavioral therapy program that helps veterans with anxiety, posttraumatic stress disorder, and alcohol use at the same time can help improve the participants lives.

co-occurring hazardous drinking, anxiety disorders, and ptsd are problematic combinations of mental health concerns experienced by deployed veterans. veterans who have been deployed are at particular risk for experiencing problems in functioning and reintegration related to mental health disorders and hazardous drinking. co-occurring anxiety and hazardous drinking heavily impact psychosocial functioning and quality of life. although cognitive behavior therapy (cbt) can promote psychological recovery through improvements in functioning and quality of life, most cbt protocols do not address co-occurring disorders, leading to inefficient and disjointed treatment. the current research seeks to adapt and test the unified protocol (up) for deployed veterans with hazardous drinking. the use of combined cbt for both anxiety disorders and hazardous drinking has the potential to more efficiently and effectively improve functioning, reduce symptoms, and promote psychosocial recovery.

Eligibility criteria:
inclusion criteria: * meeting diagnostic criteria for current anxiety disorder and * endorsing hazardous alcohol use exclusion criteria: -need for acute medically-supervised detoxification with exclusionary criteria of * high-risk suicidality * psychotic symptoms, or * cognitive impairment that could interfere with engagement in weekly psychotherapy

Keywords: veterans anxiety stress disorders, post-traumatic alcohol drinking psychosocial functioning
safety, pharmacokinetics, and pharmacodynamics of ruzasvir (mk-8408) in participants with hepatitis c infection (mk-8408-003)

Conditions: Hepatitis C Infection

Summary: this is a 3-part study of ruzasvir (mk-8408) for participants with hepatitis c infection. successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tolerated dose of ruzasvir. part i will be for participants with hepatitis c virus (hcv) genotype 3 (gt3) and will run first: part ii will be for participants with hcv genotype 1a (gt1a), and part iii will be for participants with hcv genotype 2b (gt2b). parts ii and iii may run concurrently. the primary study hypothesis is that a safe and tolerable dose of ruzasvir that reduces viral load will be found to support further clinical investigation.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>=18 to\<=37 kg/m\^2 * in general good health, except for hcv infection * clinical diagnosis of chronic hcv infection exclusively gt3 (panels a-d) or exclusively gt1a (panels e-f), or exclusively gt2b (panels g-h). * must agree to follow the smoking restrictions defined by the cru * must agree to use an acceptable method of contraception during the study and for 90 days after the last dose of ruzasvir exclusion criteria: * clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormalities or diseases * history of clinically significant hepatic disease, gilbert's disease or biliary tract disease * history of cancer (malignancy) with the exception of adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, or successfully-treated malignancies ≥10 years prior to screening * history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food * positive for hepatitis b or human immunodeficiency virus (hiv) * major surgery or donated or lost 1 unit of blood (approximately 500 ml) within 4 weeks prior to screening * participated in another investigational trial within 4 weeks prior to the screening visit * qtc interval \>=470 msec (for males) or \>= 480 msec (for females) * unable to refrain from or anticipates use of any medication (prescription and/or non-prescription) or herbal remedies beginning approximately 2 weeks prior to first study drug dose, throughout the trial until the post-trial visit * consumes \>2 glasses of alcoholic beverages per day * regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 12 months * evidence or history of chronic hepatitis not caused by hcv * previous treatment with other hcv ns5a inhibitors such as mk-8742, daclatasvir, or mk-8325 * treatment with other hcv therapies such as the hcv protease * evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (metavir score \>=3)
beneficial and harmful effects of azathioprine and allopurinol versus standard azathioprine therapy for patients with ulcerative colitis

Conditions: Colitis, Ulcerative; Colitis Ulcerative Exacerbation

Summary: azathioprine is considered first line immunomodulatory therapy for patients with ulcerative colitis. up to 50% are treatment failures or experience adverse events leading to treatment withdrawal. recent evidence suggests that the combination of allopurinol and low dose azathioprine increases the proportion of treatment responders and reduce the risk of adverse events. objectives: to evaluate the beneficial and harmful effects of low dose azathioprine and allopurinol versus standard azathioprine monotherapy in patients with ulcerative colitis.

investigator initiated, multicentre, parallel arm, open, randomised controlled trial with blinded assessment

Eligibility criteria:
inclusion criteria: * willingness to comply with all trial procedures and being available for the duration of the trial. * clinically and histologically verified ulcerative colitis eligible for treatment with thiopurines due to steroid dependence (failure to taper steroid or starting a second course of systemic steroids within 1 year) or patients with the need for rescue therapy with anti-tumornecrosisfactorα (anti-tnfα) * a sigmoidoscopy or colonoscopy showing active inflammation during the present disease flare * negative stool test for pathogen bacteria incl. clostridium difficile * informed consent. * normal tpmt genotype (homozygous wild-type). * oral 5-asa dose stable for 2 weeks exclusion criteria: * kidney disease with a glomerularfiltration rate (gfr) \< 50 ml/min. * persistent alanine aminotransferase u/l (alt) twice above upper limit of the normal range. * participation in other interventional clinical trials. * pregnancy or breastfeeding. * previous thiopurin treatment. * previous or current treatment with other biologics than anti-tnfα * not being able to comply with the study, assessed by investigator

Keywords: azathioprine allopurinol antimetabolites ulcerative colitis
examining the effects of a remote pulmonary rehabilitation program in the severe asthma population.

Conditions: Asthma

Summary: this is a randomized control trial evaluating the effect of a novel mobile application-delivered pulmonary rehabilitation program in adult severe asthma patients. the intervention will include eight weeks of exercise videos that progress in difficulty, as well as asthma-specific educational content. the primary outcome measure is change in functional exercise capacity as measured by six-minute walk distance. secondary outcome measures will include evaluation of overall feasibility, and change in cpet parameters such as vo2max. change in asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq) and praise self-efficacy score will also be evaluated.


Eligibility criteria:
inclusion criteria: * adults aged 18 years and older with a diagnosis of asthma by a respirologist. they must have severe disease defined by gina severity classification. participants must have access to a smartphone or internet browser to allow access to study content. exclusion criteria: * exclusion criteria include comorbid cardiopulmonary or musculoskeletal conditions that may impact exercise tolerance in accordance with the american thoracic society cpet guidelines
ibuprofen as a possible preventer of post bronchoscopy fever

Conditions: Post Bronchoscopy Fever

Summary: scientific background: bronchoscopy is a procedure commonly performed in the management of persistent respiratory illness. in the last decades this exam has become a routine and safe procedure even in children and there are few side-effects. however, one known side effect is transient fever and even high fever a few hours after the bronchoscopy. this side effect is not dangerous but very uncomfortable for the patients and it would be interesting to try to reduce this phenomena. this fever is due to a release of cytokines during the broncho-alveolar lavage procedure and not to sepsis. in a previous study a single dose of dexamethasone was shown to prevent the fever post bronchoscopy with no apparent detriment to the child. it is well known that steroids are immunosuppressive. even though the post-bronchoscopy fever is not caused by an infection, it seems preferable to use other anti-inflammatory drugs to fight this very inconvenient side effect. ibuprofen (nurofen\*) is known as an effective medication to reduce fever in infectious illnesses and is even considered as superior to paracetamol. it has no immunosuppressive effect and is usually well tolerated by children with very few side effects when taken in the normal therapeutic dose of 10mg/kg. the investigators postulate that a dose of nurofen prior to bronchoscopy could significantly reduce fever post bronchoscopy.


Eligibility criteria:
inclusion criteria: * under twelve years of age * all patients undergoing bronchoscopy and bronchoalveolar lavage exclusion criteria: * children with immune deficiency * allergy to nsaids * previous exacerbation of asthma due to nsaids * fever on the day of the examination * current antibiotic treatment
quality of life and pain outcomes following video-assisted thoracic surgery (vats) anatomic lung resection versus thoracotomy and anatomic lung resection

Conditions: Lung Cancer; Quality of Life; Video-assisted Thoracic Surgery (VATS); Thoracotomy

Summary: the purpose of this study is to see if different types of surgery for lung cancer have different effects on quality of life and pain. what we learn from this study may help us find new ways to improve the quality of life of lung cancer patients who have surgery.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed or suspected clinical stage i non small cell lung cancer (including carcinoid tumors) based on standard staging (ct, pet, ± mediastinoscopy). * patients offered a vats anatomic lung resection or a standard, posterolateral thoracotomy and anatomic lung resection at mskcc. * patients cannot have had prior therapy, including surgery for the current lesion, systemic chemotherapy or external beam radiotherapy. * kps ≥ 70. * synchronous primaries within one lobe. exclusion criteria: * patients who have already undergone the planned operation. * patients who cannot tolerate segmentectomy or lobectomy. * patients with locally advanced or metastatic disease found either preoperatively or at the time of operation. * patients who are non- english speaking * patients with multi-focal disease * patients with con-current cancers * patients with benign disease. * patients who are unwilling or unable to return to memorial sloan-kettering cancer center for postoperative follow-up for the first year following their operation.

Keywords: lung cancer quality of life vats thoracotomy 05-006
screening for bcrl in targeted therapy for breast cancer

Conditions: Lymphedema; Lymphedema Arm; Lymphedema of Upper Arm; Lymphedema of Upper Limb; Lymphedema of the Hands; Edema; Edema Arm; Breast Cancer Lymphedema; Breast Cancer Metastatic; Breast Cancer Stage; Breast Cancer

Summary: this a prospective, longitudinal study designed to track edema and breast cancer related lymphedema (bcrl) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. a perometer and sozo devise will be used to measure volume changes

this study will compare patients' relative arm volume changes and symptoms data from before drug therapy throughout drug treatment and for up to six months after treatment has finished. a perometer and sozo device will be used to measure volume changes all participants will be accrued at massachusetts general hospital for a target accrual of 166 participants.

Eligibility criteria:
inclusion criteria: * subjects who are receiving treatment in the mgh breast cancer center who are enrolled in a df/hcc-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or bcrl will be eligible. * subjects that will be eligible for the study include: * females between 18 and 80 years of age * with a history of breast cancer * 4 weeks or more post-surgery * with or without edema * undergoing treatment with targeted therapy for early or metastatic disease. exclusion criteria: - patients who cannot attain 90 degrees of shoulder abduction (position of measurement with perometer).

Keywords: lymphedema lymphedema arm lymphedema of upper arm lymphedema of upper limb lymphedema of the hands edema edema arm breast cancer lymphedema breast cancer metastatic breast cancer stage breast cancer